Xanthomonas maltophilia bacteremia in immunocompromised hematological patients

Scand J Infect Dis. 1994;26(2):163-70. doi: 10.3109/00365549409011780.

Abstract

Epidemiological, microbiological and clinical characteristics of 14 episodes of Xanthomonas maltophilia bacteremia in 12 seriously immunocompromised hematological patients, admitted to Rigshospitalet in Copenhagen over the 3-year period 1989-91, were evaluated. The results were compared with a randomly selected control group of 25 patients with Escherichia coli bacteremia. Hospital acquired bacteremia was more common among the patients with X. maltophilia bacteremia (p < 0.01). Treatment with broad-spectrum antibiotics before the bacteremic episode was markedly more common among the patients with X. maltophilia bacteremia (p < 0.001). The presence of a central venous catheter and previous treatment with corticosteroids were more frequent in patients with X. maltophilia bacteremia (p < 0.05). The X. maltophilia blood culture isolates were generally resistant to aminoglycosides and most beta-lactams. The mortality rates related to bacteremia caused by X. maltophilia and E. coli were 14% and 20%, respectively.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Bacterial Agents / pharmacology
  • Bacteremia / complications*
  • Bacteremia / epidemiology
  • Bacteremia / microbiology
  • Child
  • Cross Infection / epidemiology
  • Escherichia coli / isolation & purification
  • Escherichia coli Infections / complications
  • Female
  • Gram-Negative Aerobic Bacteria / isolation & purification
  • Gram-Negative Bacterial Infections / complications*
  • Gram-Negative Bacterial Infections / epidemiology
  • Hematologic Diseases / complications*
  • Humans
  • Immunocompromised Host*
  • Male
  • Middle Aged
  • Xanthomonas / drug effects
  • Xanthomonas / isolation & purification*

Substances

  • Anti-Bacterial Agents